The healthcare market is constantly changing.
This is primarily due to an aging population, improved disease prevention and management, emerging regions with demand for modern healthcare, and new diagnostics and therapies.
The most significant growth areas are in biotechnology, software, and services.
More than 10,000 transactions occur each year in this sector, with 60% in the United States and 25% in Europe.
Pharmaceuticals and biotechnology account for over 40% of the deals, followed by product and service providers in second and third place, respectively.
Almost 70% of the deals are valued at under $100M.
All companies in the pharmaceutical sector currently face multiple challenges: lower sales prices for medicinal products due to health authorities’ intervention, the rise of generics, the accumulation of constraints, and increases in costs and development times.
Furthermore, the unpredictable nature of geopolitical and regulatory changes, as well as the growth of precautionary principles, hinder predictability. Companies must adapt and restructure their strategies to remain competitive.
This necessitates innovation and a greater demand on employees to adapt and contribute to the required changes.
The group in short :
Every year More than 30 successfull transactions with 20 Senior Consultants and Partners On companies with 5 to 100 employees With a turnover of 1 to 100 Million
We are located in many countries in Europe and Africa to provide access to foreign buyers/investors:
Discuss your next step confidentially
Clarify objectives, timing and options with a senior M&A adviser.
Book a confidential meeting